Stayble Therapeutics AB Poised for Breakthrough with Phase 2b Study of STA363
Stayble Therapeutics AB is a biotech company making waves on the Swedish Stock Exchange with its promising lead candidate STA363, poised to advance to a Phase 2b study this year.
2 minutes to read